LB Pharmaceuticals Inc
LBRX
$47.78
$3.517.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 20.24% | 49.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 136.39% | 69.65% | |||
| Operating Income | -136.39% | -69.65% | |||
| Income Before Tax | -170.83% | -66.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -170.83% | -66.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -170.83% | -66.09% | |||
| EBIT | -136.39% | -69.65% | |||
| EBITDA | -136.83% | -70.14% | |||
| EPS Basic | -153.77% | -49.44% | |||
| Normalized Basic EPS | -145.70% | -61.28% | |||
| EPS Diluted | -153.77% | -49.44% | |||
| Normalized Diluted EPS | -145.70% | -61.28% | |||
| Average Basic Shares Outstanding | 6.71% | 11.16% | |||
| Average Diluted Shares Outstanding | 6.71% | 11.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||